Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy

Human Gene Therapy

Volumn 19, Issue 7, 2008, Pages 670-680

  Cipriani, Barbara ^a,d   Fridman, Arthur ^b   Bendtsen, Claus ^b   Dharmapuri, Shridar ^a   Mennuni, Carmela ^a   Pak, Irene ^b   Mesiti, Giuseppe ^a   Forni, Guido ^c   Monaci, Paolo ^a   Bagchi, Ansu ^b   Ciliberto, Gennaro ^a   Monica, Nicola La ^a   Scarselli, Elisa ^a  

^a Merck Research Laboratories   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; COMPLEMENTARY DNA; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC IMMUNIZATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; LEUKOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMID; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; SUPPRESSOR CELL;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; GENETIC VECTORS; HUMANS; INTERFERON TYPE II; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MYELOID CELLS; PREDICTIVE VALUE OF TESTS; RATS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINATION;

ADENOVIRIDAE; MUS; RATTUS;

EID: 47549112087     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.127     Document Type: Article

References (36)

1. Ambrosino, E., Spadaro, M., Iezzi, M., Curcio, C., Forni, G., Musiani, P., Wei, W.Z., and Cavallo, F. (2006). Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66, 7734-7740.
2. Astolfi, A., Landuzzi, L., Nicoletti, G., De Giovanni, C., Croci, S., Palladini, A., Ferrini, S., Iezzi, M., Musiani, P., Cavallo, F., Forni, G., Nanni, P., and Lollini, P.L. (2005). Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/ neu-positive basal-like mammary carcinoma. Am. J. Pathol. 166, 1205-1216.
3. Aurisicchio, L., Mennuni, C., Giannetti, P., Calvaruso, F., Nuzzo, M., Cipriani, B., Palombo, F., Monaci, P., Ciliberto, G., and Monica, N.L. (2007). Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in non-human primates. Int. J. Cancer 120, 2290-2300.
4. Bargmann, C.I., Hung, M.C., and Weinberg, R.A. (1986). The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230.
5. Cappelletti, M., Zampaglione, I., Rizzuto, G., Ciliberto, G., La Monica, N., and Fattori, E. (2003). Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. J. Gene Med. 5, 324-332.
6. Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289.
7. Cavallo, F., Curcio, C., and Forni, G. (2005a). Immunotherapy and immunoprevention of cancer: Where do we stand? Expert Opin. Biol. Ther. 5, 717-726.
8. Cavallo, F., Offringa, R., van der Burg, S.H., Forni G., and Meilief, C.J.M. (2005b). Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175-213.
9. Di Carlo, E., Diodoro, M.G., Boggio, K., Modesti, A., Modesti, M., Nanni, P., Forni, G., and Musiani, P. (1999). Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 79, 1261-1269.
10. + myeloid cells. J. Immunol. 166, 5398-5406.
11. Gallo, P., Dharmapuri, S., Nuzzo, M., Maldini, D., Iezzi, M., Cavallo, F., Musiani, P., Forni, G., and Monaci, P. (2005). Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113, 67-77.
12. Gallo, P., Dharmapuri, S., Nuzzo, M., Maldini, D., Cipriani, B., Forni, G., and Monaci, P. (2007). Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int. J. Cancer 120, 574-584.
13. Giannetti, P., Facciabene, A., La Monica, N., and Aurisicchio, L. (2006). Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J. Immunol. Methods 316, 84-96.
14. Gilbert, S.C., Schneider, J., Hannan, C.M., Hu, J.T., Plebanski, M., Sinden, R., and Hill, A.V. (2002). Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039-1045.
15. Gurunathan, S., Klinman, D.M., and Seder, R.A. (2000). DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974.
16. Jones, T.D., Hanlon, M., Smith, B.J., Heise, C.T., Nayee, P.D., Sanders, D.A., Hamilton, A., Sweet, C., Unitt, E., Alexander, G., Lo, K.M., Gillies, S.D., Carr, F.J., and Baker, M.P. (2004). The development of a modified human IFN-α2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J. Interferon Cytokine Res. 24, 560-572.
17. Lucchini, F., Sacco, M.G., Hu, N., Villa, A., Brown, J., Cesano, L., Mangiarini, L., Rindi, G., Kindl, S., Sessa, F., Vezzoni, P., and Clerici, L. (1992). Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett. 64, 203-209.
18. Melani, C., Chiodoni, C., Forni, G., and Colombo, M.P. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145.
19. Mennuni, C., Calvaruso, F., Facciabene, A., Aurisicchio, L., Storto, M., Scarselli, E., Ciliberto, G., and La Monica, N. (2005). Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117, 444-455.
20. Montgomery, D.L., Shiver, J.W., Leander, K.R., Perry, H.C., Friedman, A., Martinez, D., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. (1993). Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol. 12, 777-783.
21. Nanni, P., Landuzzi, L., Nicoletti, G., De Giovanni, C., Rossi, I., Croci, S., Astolfi, A., Iezzi, M., Di Carlo, E., Musiani, P., Forni, G., and Lollini, P.L. (2004). Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J. Immunol. 173, 2288-2296.
22. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174, 4228-4236.
23. Parker, K.C., Bednarek, M.A., and Coligan, J.E. (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175.
24. Polo, J.M., and Dubensky, T.W., Jr. (2002). Virus-based vectors for human vaccine applications. Drug Discov. Today 7, 719-727.
25. Quaglino, E., Iezzi, M., Mastini, C., Amici, A., Pericle, F., Di Carlo, E., Pupa, S.M., De Giovanni, C., Spadaro, M., Curcio, C., Lollini, P.L., Musiani, P., Forni, G., and Cavallo, F. (2004). Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res. 64, 2858-2864.
26. Quaglino, E., Mastini, C., Iezzi, M., Forni, G., Musiani, P., Klapper, L.N., Hardy, B., and Cavallo, F. (2005). The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 23, 3280-3287.
27. Serafini, P., Borrello, I., and Bronte, V. (2006). Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65.
28. Shak, S. (1999). Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71-77.
29. Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R., Davies, M.E., Evans, R.K., Zhang, Z.Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., and Emini, E.A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
30. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
31. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
32. Stephenson, J. (1998). Defective adenoviruses as novel vaccines for the Flaviviridae. Clin. Diagn. Virol. 10, 187-194.
33. Vieweg, J., Su, Z., Dahm, P., and Kusmartsev, S. (2007). Reversal of tumor-mediated immunosuppression. Clin. Cancer Res. 13, 727s-732s.
34. Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2), 1-13.
35. Zea, A.H., Rodriguez, P.C., Atkins, M.B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., Mier, J., and Ochoa, A.C. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 65, 3044-3048.
36. Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307.